Shire is facing testing times after buying United States-based Baxalta in its biggest ever deal, leading to inevitable upheaval and challenges.
Both companies in the past two years were just below the middle of the pack on most employee satisfaction measures.

Analyst as UBS, monitoring the situation have concluded “Neither markets nor employees seem as confident as management that things are on track,” that’s why UBS has reduced its 12-month price target to 40.95 pounds a share from 45 pounds while rating the stock neutral.

According to the this analysis the company is coming 24th out of 26 biopharmaceutical companies on “overall satisfaction.

On the otherside  Shire’s chief human resources officer, Joanne Cordeiro, said the drugmaker’s own surveys painted a more encouraging picture.

“We are in the late stages of significant corporate transformation as we have evolved into the global leader in rare diseases,” she said.

“Our internal engagement marks for Shire are high despite these changes. We are focussed on working to ensure we continue to build the best organisation for our employees, patients and shareholders.”

Read the full article: The New York Times